ArticleEmerging infectious diseases2011
Intravenous artesunate for severe malaria in travelers, Europe.
Article in Emerging infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Systematic analysis of direct antiglobulin test results in post-artesunate delayed haemolysis.Malaria journal · 2021Pooled it
- Prevalence and risk factors related to poor outcome of patients with severe Plasmodium vivax infection: a systematic review, meta-analysis, and analysis of case reports.BMC infectious diseases · 2020Pooled it
- Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria.BMC infectious diseases · 2016Trial
- Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children.BMC infectious diseases · 2015Trial
- Recent Advancement in Drug Development for Treating Malaria using Herbal Medicine and Nanotechnological Approach.Current pharmaceutical design · 2025Review
- High malaria parasitemia in an Italian man and severe delayed hemolytic anemia.Clinical case reports · 2024Article
- Severe coinfection of dengue and malaria: A case report.Clinical case reports · 2024Article
- Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems.Journal of Alzheimer's disease : JAD · 2024Review
- The Antimalarial Drug Artesunate Mediates Selective Cytotoxicity by Upregulating HO-1 in Melanoma Cells.Biomedicines · 2023Article
- Use of artesunate in the treatment of severe imported malaria in France: review of the effectiveness and real-life safety in two French university hospitals.BMC infectious diseases · 2023Observational
- Post-treatment haemolysis is common following oral artemisinin combination therapy of uncomplicated malaria in travellers.Journal of travel medicine · 2023Observational
- Delayed autoimmune haemolytic anaemia after artesunate therapy for severe malaria.BMJ case reports · 2022Article
- Article
- Delayed haemolysis after treatment with intravenous artesunate in patients with severe malaria in India.Malaria journal · 2020Observational
- [PGE1-assisted treatment of microcirculation disturbance in complicated falciparum malaria].Der Anaesthesist · 2019Article
- Clinical illness and outcomes in Nigerian children with persistent early-appearing anaemia following initiation of artemisinin-based combination treatments of uncomplicated falciparum malaria.Parasite (Paris, France) · 2019Article
- A 4-Day Incubation Period ofOpen forum infectious diseases · 2019Article
- Artesunate-Induced Severe Autoimmune Hemolytic Anemia in Complicated Malaria.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2018Article
- Development of Delayed Hemolytic Anemia After Treatment with Oral Artemether-Lumefantrine in Two Patients with Severe Falciparum Malaria.The American journal of tropical medicine and hygiene · 2017Article
- Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated Plasmodium falciparum malaria -associated anaemia in Nigerian children during seven years of adoption as first-line treatments.Infectious diseases of poverty · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multicenter trials in Southeast Asia have shown better survival rates among patients with severe malaria, particularly those with high parasitemia levels, treated with intravenous (IV) artesunate than among those treated with quinine. In Europe, quinine is still the primary treatment for severe malaria. We conducted a retrospective analysis for 25 travelers with severe malaria who returned from malaria-endemic regions and were treated at 7 centers in Europe. All patients survived. Treatment with IV artesunate rapidly reduced parasitemia levels. In 6 patients at 5 treatment centers, a self-limiting episode of unexplained hemolysis occurred after reduction of parasitemia levels. Five patients required a blood transfusion. Patients with posttreatment hemolysis had received higher doses of IV artesunate than patients without hemolysis. IV artesunate was an effective alternative to quinine for treatment of malaria patients in Europe. Patients should be monitored for signs of hemolysis, especially after parasitologic cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.